Could an antibiotic beat eye cancer? new trial tests doxycycline for lymphoma
NCT ID NCT01820910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the antibiotic doxycycline as a first treatment for a rare type of eye lymphoma (OAMZL) that may be linked to a bacterial infection. 44 newly diagnosed patients took doxycycline for several months. The goal was to see if eradicating the infection could control the lymphoma and delay or avoid the need for stronger treatments like chemotherapy or radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- doxycycline
- What this could lead to
- If successful, this antibiotic approach could provide a less toxic, chemotherapy-free treatment option for this rare eye lymphoma.
- What could go wrong
- This is a small, early-phase trial (44 people) without a comparison group. The lymphoma may not respond or could return after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA OF OCULAR ADNEXAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AO Ospedali Riuniti Papardo Piemonte
Messina, Italy
-
Ematologia
Parma, Italy
-
Molinette 1
Torino, Italy
-
Ospedale Civile
Piacenza, Italy
-
Ospedale San Raffaele
Milan, Italy
-
Ospedale dell'Angelo
Venezia, Italy
-
Spedali Civili Di Brescia
Brescia, Italy
-
Università La Sapienza
Rome, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.